The role and effect of Bosutinib in the treatment of ALS

Bosutinib is a targeted therapy drug that is a tyrosine kinase inhibitor (TKI) and is mainly used to treat certain types of cancer such as chronic myelogenous leukemia (CML). It reduces the proliferation and spread of tumor cells by inhibiting the tyrosine kinase activity related to the BCR-ABL fusion gene. However, bosutinib is not a first-line drug for the treatment of ALS (ALS), and it is not approved for the treatment of ALS or other neurodegenerative diseases.

ALS, also known as amyotrophic lateral sclerosis (ALS), is a disease that causes the gradual death of nerve cells, mainly affecting the motor nerves. Although some drugs (such as riluzole) have been approved to relieve the symptoms and delay the progression of ALS, bosutinib does not have a direct mechanism of action on ALS. The main effect of bosutinib is to target the BCR-ABL fusion gene in leukemia. It does not directly affect the neurodegenerative process of ALS. Therefore, the efficacy of using bosutinib to treat ALS has not been clearly demonstrated.

Currently, medical research and clinical trials do not provide sufficient evidence regarding the use of bosutinib in ALS. Bosutinib is mainly used to treat certain types of leukemia, and the pathogenesis of ALS is quite different from that of these hematological diseases. The pathological characteristics of ALS are related to the degeneration and death of nerve cells, which does not match the targeted therapeutic effect of bosutinib. Therefore, bosutinib cannot replace existing ALS treatment options.

While bosutinib may show significant efficacy in the treatment of leukemia, there is currently no evidence to support its efficacy in ALS. For patients with ALS, treatment options based on drugs such as riluzole remain the current standard of care. In the future, if there are new clinical trials or studies showing that bosutinib has potential efficacy in ALS, it may be considered as a new direction for research. However, there is still a lack of scientific basis for the use of bosutinib in the treatment of ALS at this stage. Patients should consult a neurologist during the treatment process to choose a suitable treatment method.

Reference materials:https://go.drugbank.com/drugs/DB06616